Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6603
-0.0307-4.44%
Pre-market: 0.67900.0187+2.83%08:57 EDT
Volume:3.23M
Turnover:2.17M
Market Cap:142.96M
PE:-1.11
High:0.7000
Open:0.7000
Low:0.6550
Close:0.6910
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:0.99
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5922
EPS(LYR):-0.5922
ROE:-83.84%
ROA:-43.72%
PB:1.16
PE(LYR):-1.11

Loading ...

Tenaya Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
16 hours ago

Tenaya to present new RIDGE-1 TN-401 gene therapy data at ASGCT 2026

Reuters
·
Apr 27

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data From Ridge™-1 Phase 1B/2 Clinical Trial of Tn-401 Gene Therapy in Adults With Pkp2-Associated Arvc at Asgct 2026

THOMSON REUTERS
·
Apr 27

Tenaya Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 16

Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating

TIPRANKS
·
Apr 14

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 12

Tenaya Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 12

Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027

Reuters
·
Mar 12

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

TIPRANKS
·
Mar 12

Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate

Benzinga
·
Mar 12

BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million

Reuters
·
Mar 12

Tenaya Therapeutics Q4 Operating Expenses USD 20.775 Million

THOMSON REUTERS
·
Mar 12

Press Release: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 12

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

GlobeNewswire
·
Mar 09

Tenaya Therapeutics: Alnylam Partnership Validates Cardiovascular Platform and Supports Long-Term Buy Thesis

TIPRANKS
·
Mar 06

Tenaya Therapeutics: Alnylam Collaboration De-Risks Platform and Expands Cardiovascular Upside, Supporting Buy Rating

TIPRANKS
·
Mar 06

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Reuters
·
Mar 05

Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration

TIPRANKS
·
Mar 05

BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics

Reuters
·
Mar 05

Tenaya Therapeutics Inc - Co to Validate up to 15 Gene Targets Under Agreement

THOMSON REUTERS
·
Mar 05